The weight-loss and diabetes injectables have seen a surge in demand primarily in the U.S., buoying Novo Nordisk’s profits in the first half of 2023. Read More
© 2010-2022 Billy Tang
Supported By Growth SpeedUp Company
© 2010-2022 Billy Tang
Supported By Growth SpeedUp Company
Subscribe now to keep reading and get access to the full archive.